Asia On The Move: New CFDA Directors, AZ China GM
This article was originally published in PharmAsia News
The China FDA has appointed several key directors and UK drug maker AstraZeneca has quietly changed its China head to a locally grown executive. Personnel changes also take place in major domestic maker Hisun, the China State Administration for Industry and Commerce (SAIC), Acucela and AdvaMed.
You may also be interested in...
A new study in over 400 people reignites fears about the apparent low efficacy of Chinese COVID-19 vaccines, especially among the elderly, and adding to the debate around the need for booster shots.
The latest developments around data security and protection signal the need for rigorous implementation of procedures and potential significant cost increases for pharma and other companies operating in China.
There is talk about offering booster shots to people who have already been fully vaccinated against COVID-19 in China and it’s increasingly clear that the mRNA vaccine from BioNTech/Fosun nearing approval could be the answer. Meanwhile, some Asian countries are turning away from Chinese coronavirus vaccines.